Clinical Trials · NCT00587431
Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Enrollment
- 102
- Start date
- Jul 2003
- Locations
- 1 site, United States
- Primary endpoint
- PSA of <_ 0.05 ng/ml After Radical Prostatectomy or Radiation Therapy and PSA <_ 2.0 ng/ml for Patients With Clinical Metastases Without Prior Definitive Therapy